Hanmi Pharmaceutical Co. is exporting two types of three-substance combination hypertension drug to Mexico, becoming the first Korean drug maker to launch such medicines in the Latin American market.
Hanmi Pharmaceutical announced on Sept. 11 that it has signed an agreement with Silanes, a medium-sized pharmaceutical company in Mexico, to export its dyslipidemia and hypertension treatments, Amosartan Plus and Amosartan Q. It will take steps to get approval for sales of its products in Mexico.
The company plans to export US$10 million (11.87 billion won) worth of the two products to Silanes over five years, while Silanes plans to win licenses for both products in the second half of 2020 and start marketing them in the second quarter of 2021.
Hanmi Pharmaceutical has received the first milestone from Silanes, and will receive additional milestones after the product launch. The two companies agreed not to disclose the amount of the milestones.
Amosartan Plus and Amosartan Q are improvements on Amosartan, the country’s first novel compound treatment for hypertension.
Amosartan Plus is added with diuretic compound Chlortalidone which can have an additional coercion effect, while Amosartan Q is added with hyperlipidemia compound rosuvastatin for hypertension patients with dyslipidemia.
Hanmi Pharmaceutical’s Amosartan is currently being exported to the global market under the name of Koza XQ through global leading pharmaceutical firm MSD. Its dual-action drug for hyperlipidemia, Rosuzet, is also being registered in foreign countries through MSD.